Advise patients that if a dose of dasatinib is missed, the next dose should be taken at the regularly scheduled time; the dose should not be doubled. Advise patients who are taking Sprycel film-coated tablets to inform their clinician if they are lactose intolerant. Phyrago tablets do not ...
Financial Guidance Bristol Myers Squibb is providing key 2025 non-GAAP line-item guidance assumptions as outlined below. We estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid, Pomalyst, Spry...
Earnings Calendar Earnings News Earnings Analysis Earnings Calls Transcripts Terms Of Use Privacy Market Data Sources © 2025 Seeking Alpha
Bristol Myers Squibb posted fourth quarter revenues of $12.3 billion, an increase of 8%, or 9% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and higher demand forEliquis, partially offset by the impact of generics onSprycel, Revlimid, AbraxaneandPomalyst. U...
Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%, or 9% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and higher demand for Eliquis, partially offset by the impact of generics on Sprycel, Revlimid and Abraxane. U....
SPRYCEL (dasatinib) is indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior thera...
Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to ...
Sprycel 1,011 1,032 (2)% 600 608 (1)% Yervoy 966 765 26% 622 511 22% Abraxane 610 608 — 459 423 9% Empliciti 171 194 (12)% 102 118 (14)% Reblozyl 240 63 ** 208 63 ** Inrebic 32 27 19% 30 27 11% Onureg 27 — N/A 26 — N/A Zeposia 46...
Sprycel 564 549 3 % 351 319 10 % Yervoy 471 385 22 % 304 254 20 % Abraxane 297 166 79 % 214 122 75 % Empliciti 91 94 (3) % 53 63 (16) % Reblozyl 115 — N/A 104 — N/A Inrebic 15 5...
Anti-PD-1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.